|
WO2005108418A1
|
|
Compounds for specific viral target
|
|
US2005176641A1
|
|
Long lasting natriuretic peptide derivatives
|
|
CN1964989A
|
|
Long lasting insulin derivatives and methods thereof
|
|
EP1530588A2
|
|
Long lasting natriuretic peptide derivatives
|
|
WO02066511A2
|
|
Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
|
|
EA006484B1
|
|
Long lasting growth hormone releasing factor derivatives
|
|
US7144854B1
|
|
Long lasting anti-angiogenic peptides
|
|
US7090851B1
|
|
Long lasting fusion peptide inhibitors of viral infection
|
|
CA2383794A1
|
|
Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents
|
|
US6514500B1
|
|
Long lasting synthetic glucagon like peptide {GLP-!}
|
|
US6887470B1
|
|
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
|
US6706892B1
|
|
Pulmonary delivery for bioconjugation
|
|
TW200602353A
|
|
Modified secretin and method of synthesizing thereof
|
|
US6849714B1
|
|
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
|
CA2363712A1
|
|
Long lasting insulinotropic peptides
|
|
AU5139300A
|
|
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
|
CN1698881A
|
|
Long lasting fusion peptide inhibitors of viral infection
|
|
US6440417B1
|
|
Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatments
|
|
WO9948536A2
|
|
Delivery of long lasting therapeutic agents by forming covalent attachments in vivo
|
|
US6107489A
|
|
Extended lifetimes in vivo renin inhibitors
|
